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Abstract
Background: To evaluate the metabolic changes in urinary steroids in pre- and post-menopausal women and men
with papillary thyroid carcinoma (PTC).
Methods: Quantitative steroid profiling combined with gas chromatography-mass spectrometry was used to
measure the urinary concentrations of 84 steroids in both pre- (n = 21, age: 36.95 ± 7.19 yr) and post-menopausal
female (n = 19, age: 52.79 ± 7.66 yr), and male (n = 16, age: 41.88 ± 8.48 yr) patients with PTC. After comparing
the quantitative data of the patients with their corresponding controls (pre-menopause women: n = 24, age: 33.21
± 10.48 yr, post-menopause women: n = 16, age: 49.67 ± 8.94 yr, male: n = 20, age: 42.75 ± 4.22 yr), the levels of
steroids in the patients were normalized to the mean concentration of the controls to exclude gender and
menopausal variations.
Results: Many urinary steroids were up-regulated in all PTC patients compared to the controls. Among them, the
levels of three active androgens, androstenedione, androstenediol and 16a-hydroxy DHEA, were significantly higher
in the pre-menopausal women and men with PTC. The corticoid levels were increased slightly in the PTC men,
while progestins were not altered in the post-menopausal PTC women. Estrogens were up-regulated in all PTC
patients but 2-hydroxyestrone and 2-hydroxy-17b-estradiol were remarkably changed in both pre-menopausal
women and men with PTC. For both menopausal and gender differences, the 2-hydroxylation, 4-hydroxylation, 2-
methoxylation, and 4-methoxylation of estrogens and 16a-hydroxylation of DHEA were differentiated between pre-
and post-menopausal PTC women (P < 0.001). In particular, the metabolic ratio of 2-hydroxyestrone to 2-hydroxy-
17b-estradiol, which could reveal the enzyme activity of 17b-hydroxysteroid dehydrogenase, showed gender
differences in PTC patients (P <1×1 0
-7).
Conclusions: These results are expected be helpful for better understanding the pathogenic differences in PTC
according to gender and menopausal conditions.
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Background
Papillary thyroid carcinoma (PTC) is the commonest of
all thyroid carcinomas and is well-differentiated. The
incidence of PTC is three times higher in women than
men [1,2] but this gender difference decreases after
menopause [3]. The gender differences and menopausal
conditions in the incidence of PTC suggest that the
pathogenesis and development of PTC might be affected
by sex steroids, particularly androgens and estrogens
[3-11].
The biological activity of estrogens is differentiated by
an interaction with both estrogen receptors a and b
(ERa and ERb). Especially, the level of ERa is higher in
PTC cells than other thyroid carcinoma cells and nor-
mal cells [12]. In addition, the level of ERa is higher in
p r e - m e n o p a u s a lw o m e nt h a ni np o s t - m e n o p a u s a l
women and men with PTC [7]. The androgen receptor
(AR), which mediates the biological activity of
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[13-16]. The levels of AR in thyroid cells are higher in
men than in women, and higher in PTC cells than in
normal cells [14-16].
Although sex steroids including estrogens and andro-
gens might be associated with both the growth and pro-
gression of PTC, the changes in steroids along with
gender differences and menopause in PTC have not
been well defined. No data is available on the metabolic
alteration of steroid profiling between pre- and post-
menopausal women, and men with PTC. Therefore, in
this study, 84 steroids (including 25 androgens, 17 estro-
gens, 23 corticoids, 14 progestins, and 5 sterols) in urine
samples obtained from pre- and post-menopausal
women, and men with PTC were evaluated against the
corresponding control groups matched for gender and
menopausal condition using gas chromatography-mass
spectrometry (GC-MS)-based steroid signatures [17].
Firstly, the urinary levels of steroids in the PTC patients
and their controls in the three groups (pre- and post-
menopausal women and men) were measured and sig-
nificance in the individual groups was evaluated using a
Student’s t-test. Secondly, the steroid levels in each
patient group were normalized to those of the corre-
sponding controls to exclude the nature of menopausal
and gender differences. The change in normalized ster-
oids profiling between the three groups was evaluated
b yo n e - w a yv a r i a n c ea n a l y s i s( o n e - w a yA N O V A ) .
Finally, the metabolic patterns of steroids in the three
groups were interpreted by partial least-squares-discri-
mination analysis (PLS-DA), and examined by ANOVA.
Methods
Subjects and sample-collection
Urine samples were collected from pre-menopausal
women (n = 21, age: 36.95 ± 7.19 yr, BMI: 23.72 ± 4.69
kg/m
2), post-menopausal women (n = 19, age: 52.79 ±
7.66 yr, BMI: 24.46 ± 2.76 kg/m
2) and men (n = 16, age:
41.88 ± 8.48 yr, BMI: 25.52 ± 3.31 kg/m
2)w i t hP T Ca s
well as from healthy subjects as the controls for the pre-
menopausal women (n = 24, age: 33.21 ± 10.48 yr, BMI:
23.52 ± 3.94 kg/m
2), post-menopausal women (n = 16,
age: 49.67 ± 8.94 yr, BMI: 23.02 ± 3.38 kg/m
2)a n dm e n
(n = 20, age: 42.75 ± 4.22 yr, BMI: 24.58 ± 2.49 kg/m
2)
at the Severance Hospital (Seoul, Korea). All study sub-
jects underwent the same diagnostic procedures, i.e.,
ultrasound and fine needle aspiration (FNA) as detailed
by the American Joint Committee on Cancer staging.
Patients with a history of cancer of the cervix, breast,
endometrium, or head and neck, and respiratory papillo-
matosis as well as the post-menopausal women, who
have received the estrogen replacement therapy, were
excluded. The PTC not invaded the adjacent tissues or
showed no spread to nearby lymph nodes. The healthy
gender- and age-matched controls had no evidences of
benign or malignant thyroid diseases. The first morning
urine samples were collected after fasting for at least 12
hours and the patient samples were taken before thyroi-
dectomy. All subjects showed normal thyroid function
(T3: 104.11 ± 19.1 ng/dL, T4: 11.16 ± 2.56 μg/dL, TSH:
1.02 ± 0.31 μIU/mL) and were not treated with or
exposed to any drugs including the contraceptive. The
experimental protocol (4-2009-0424) was approved by
the IRB Committee of the Human Research Protection
Center at the Severance Hospital and an informed con-
sent was signed by all subjects. The levels of urinary
steroids were calibrated by the creatinine values using
Jaffé’s method [18].
Chemicals and materials
The reference standards of the 84 steroids examined in
this study (Table 1) were obtained from Sigma (St.
Louis, MO), Steraloids (Newport, RI), and NARL (Pum-
ble, Australia). The internal standards, 16,16,17-d3-tes-
tosterone and methyltestosterone for 25 androgens,
2,4,16,16-d4-estradiol for 17 estrogens, 9,11,12,12-d4-
cortisol for 23 corticoids, 2,2,4,6,6,17a,21,21,21-d9-pro-
gesterone and 2,2,4,6,6,21,21,21-d8-17a-hydroxyproges-
terone for 14 progestins, and 2,2,3,4,4,6-d6-cholesterol
for 5 sterols were purchased from NARL and C/D/N
isotopes (Pointe-Claire, Quebec, Canada). For solid-
phase extraction (SPE), an Oasis HLB cartridge (3 mL,
60 mg; Waters, Milford, MA) was preconditioned with 3
mL of methanol followed by 3 mL of deionized water.
Sodium acetate (reagent grade), acetic acid (glacial,
99.99+%) and L-ascorbic acid (reagent grade) were
obtained from Sigma. A solution of b-glucuronidase was
p u r c h a s e df r o mR o c h eD i a g n o s t i c sG m b H( M a n n h e i m ,
Germany). The trimethylsilylating (TMS) agents, N-
methyl-N-trifluorotrimethylsilyl acetamide (MSTFA),
ammonium iodide (NH4I), and dithioerythritol (DTE)
were purchased from Sigma. All organic solvents used
were of analytical or HPLC grade and were purchased
from Burdick & Jackson (Muskegan, MI). Deionized
water was prepared using a Milli-Q purification system
(Millipore; Billerica, MA).
Sample preparation
Quantitative steroid profiling was performed using a
previous technique [17]. Briefly, a urine sample (2 mL)
spiked with 20 μL of 7 internal standards (d3-testoster-
one and d4-estradiol: 1 μg/mL, d4-cortisol and d8-17a-
hydroxyprogesterone: 5 μg/mL, methyltestosterone, d9-
progesterone and d6-cholesterol: 10 μg/mL) was loaded
into the Oasis HLB™ SPE cartridge and washed with 2
mL water. After elution twice with 2 mL of methanol,
the combined methanol was evaporated under a stream
of nitrogen and 1 mL of 0.2 M acetate buffer (pH 5.2),
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Page 2 of 14Table 1 Concentrations of urinary steroids in pre-menopausal PTC women and control
Steroids Concentration
a (mean ± SD) P-value
Controls
(n = 24)
PTC
(n = 21)
Controls : PTC
Androgens
Dihydrotestosterone 65.79 ± 47.43 118.67 ± 61.89 < 0.005
Epidihydrotestosterone 20.21 ± 16.70 44.85 ± 18.85 < 0.0007
Dehydroepiandrosterone 151.34 ± 84.40 216.29 ± 93.00 < 0.02
Testosterone 64.73 ± 45.54 116.60 ± 24.77 < 0.03
Epitestosterone 82.61 ± 49.75 109.66 ± 42.13 NS
b
5a-androstan-3a,17b-diol 137.28 ± 90.96 202.60 ± 259.73 NS
5a-androstan-3b,17b-diol 20.00 ± 11.75 (3) 42.54 (1) NC
c
5b-androstan-3a,17b-diol 204.52 ± 149.53 248.07 ± 336.60 NS
5b-androstan-3a,17a-diol 70.50 ± 49.49 107.26 ± 105.68 NS
5b-androstan-3b,17a-diol 5.42 ± 1.69 (4) 6.30 ± 1.45 (3) NC
5a-androstan-3b,17a-diol 21.17 ± 14.55 41.20 ± 28.43 NS
5a-androstan-3a,17a-diol 33.64 ± 26.33 53.18 ± 41.56 NS
5b-androstan-3b,17b-diol 8.75 (1) 36.84 ± 53.75 (4) NC
Androstenedione 59.17 ± 50.56 96.93 ± 39.56 < 0.01
Androstenediol 51.71 ± 31.61 96.27 ± 33.98 < 0.0002
Androsterone 7826.70 ± 5459.40 24675.61 ± 23074.97 < 0.004
Etiocholanolone 7074.80 ± 4371.84 21993.33 ± 14558.44 < 0.0002
11-keto-androsterone +
11-keto-etiocholanolone
439.95 ± 320.79 2048.15 ± 1749.63 < 0.0005
11b-hydroxyandrosterone 2413.61 ± 1411.53 5197.95 ± 4501.89 < 0.01
11b-hydroxyetiocholanolone 1185.01 ± 873.09 2598.36 ± 1740.91 < 0.003
5b-dihydrotestosterone 3.97 ± 2.92 21.71 ± 9.26 < 0.00008
16a-hydroxy-DHEA 127.76 ± 67.50 285.48 ± 147.21 < 0.0002
Epiandrosterone 33.26 ± 26.59 49.45 ± 29.48 NS
5a-Androstanedione 36.43 ± 15.15 (11) 59.43 ± 12.34 (4) NC
Estrogens
Estrone 71.16 ± 60.17 165.12 ± 138.61 < 0.008
17b-estradiol 20.78 ± 19.43 52.64 ± 42.82 < 0.008
Estriol 69.12 ± 55.60 197.03 ± 403.37 NS
2-hydroxyestrone 298.38 ± 272.41 126.11 ± 63.97 < 0.007
2-hydroxy-17b-estradiol 84.88 ± 60.34 283.06 ± 247.77 < 0.002
4-hydroxyestrone 72.78 ± 57.37 119.25 ± 54.27 < 0.02
4-hydroxy-17b-estradiol 37.69 ± 30.34 91.53 ± 49.54 < 0.0003
2-methoxyestrone 53.79 ± 96.35 94.21 ± 48.47 NS
2-methoxy-17b-estradiol 28.85 ± 23.85 43.09 ± 18.79 NS
4-methoxyestrone 36.30 ± 32.13 61.86 ± 29.64 < 0.04
4-methoxy-17b-estradiol 29.38 ± 19.95 61.79 ± 37.91 < 0.02
17-epiestriol 18.07 ± 8.07 97.53 ± 56.54 < 0.003
16-epiestriol 37.43 ± 16.97 83.48 ± 68.51 < 0.02
17a-estradiol 2.18 ± 1.98 (2) ND NC
2-hydroxyestriol 2.37 ± 2.74 85.99 ± 63.04 < 0.002
16-keto-17b-estradiol +
16a-hydroxyestrone
20.79 ± 11.75 70.92 ± 81.33 < 0.01
Corticoids
Cortisol 276.27 ± 348.99 194.98 ± 121.70 NS
Allodihydrocortisol 38.87 ± 26.40 24.27 ± 18.96 NS
Corticosterone 37.33 ± 28.36 54.26 ± 24.03 NS
Allodihydrocorticosterone 33.18 ± 26.19 42.48 ± 18.15 NS
Dihydrodeoxycorticosterone 97.57 ± 145.03 90.54 ± 53.46 NS
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Page 3 of 14100 μL of 0.2% L-ascorbic acid, and 50 μLo fb-glucuro-
nidase were then added. After incubation at 55°C for 3
h, the solution was extracted twice with 2.5 mL of ethyl
acetate: n-hexane (2:3, v/v). The combined organic sol-
vents were evaporated using a N2 evaporator at 40°C
and dried further in a vacuum desiccator over P2O5-
KOH for at least 30 min. Finally, the dried residue was
derivatized with MSTFA/NH4I/DTE (40 μL; 500:4:2, v/
w/w) at 60°C for 20 min, and 2 μL of the resulting
mixture was subjected to GC-MS in selected-ion moni-
toring (SIM) mode.
Instrumental conditions
GC-MS was performed using an Agilent 6890 Plus gas
chromatograph interfaced with a single-quadrupole Agi-
lent 5975 MSD at an electron energy of 70 eV and ion
source temperature of 230°C. Each sample (2 μL) was
injected in split mode (10:1) at 280°C and separated
Table 1 Concentrations of urinary steroids in pre-menopausal PTC women and control (Continued)
11-deoxycorticosterone 43.68 ± 27.30 48.25 ± 19.29 NS
11-deoxycortisol 59.55 ± 42.52 53.88 ± 37.00 NS
Cortisone 700.66 ± 691.13 828.94 ± 783.61 NS
Allotetrahydrocortisol 6987.19 ± 6000.57 14415.42 ± 17559.79 NS
21-deoxycortisol 69.17 ± 45.07 89.61 ± 80.03 NS
11-dehydrocorticosterone 131.08 ± 121.05 92.97 ± 93.87 NS
Tetrahydrodeoxycortisol 502.93 ± 336.31 547.57 ± 293.54 NS
Tetrahydrocortisone 12623.53 ± 9093.38 14081.85 ± 11546.70 NS
Tetrahydrocortisol 6038.33 ± 4364.60 10488.74 ± 9218.05 NS
Tetrahydrodeoxycorticosterone 72.07 ± 90.74 76.89 ± 88.78 NS
Tetrahydrocorticosterone 353.41 ± 307.84 589.34 ± 321.77 < 0.02
11-dehydrotetrahydrocorticosterone 1403.89 ± 610.28 992.50 ± 677.32 NS
a-cortolone 4989.28 ± 3076.48 5749.11 ± 3617.93 NS
b-cortolone 2030.16 ± 1204.44 2745.91 ± 1714.17 NS
20a-dihydrocortisone 340.09 ± 272.98 423.71 ± 252.98 NS
a-cortol 921.30 ± 645.85 884.54 ± 634.69 NS
b-cortol 2296.04 ± 1382.42 2602.54 ± 1638.69 NS
20a-dihydrocortisol 209.95 ± 260.36 130.72 ± 105.39 NS
Progestins
Pregnenolone 44.36 ± 33.00 73.78 ± 32.67 < 0.008
Progesterone 45.35 (1) 194.29 (1) NC
5b-dihydroprogesterone 7.23 ± 5.09 7.88 (1) NC
5a-dihydroprogesterone 53.83 ± 26.13 20.36 ± 25.60 < 0.04
20a-hydroprogesterone 125.50 ± 189.43 153.23 ± 126.74 NS
Epipregnanolone 19.10 ± 17.42 29.50 ± 12.29 NS
Pregnanolone 717.51 ± 900.30 1305.74 ± 2701.21 NS
Allopregnanolone 198.24 ± 255.64 188.66 ± 240.25 NS
Isopregnanolone 33.41 ± 13.44 73.87 ± 50.59 < 0.02
Pregnanediol 7025.27 ± 8837.04 14031.18 ± 31235.57 NS
Pregnanetriol 2874.08 ± 1477.34 5021.37 ± 4085.30 < 0.04
17a-hydroxypregnenolone 57.89 ± 42.96 87.99 ± 40.07 < 0.03
17a-hydroxyprogesterone 53.61 ± 43.13 (6) 97.95 ± 63.76 (2) NC
11b-hydroxyprogesterone 938.19 ± 726.72 1557.51 ± 1150.75 < 0.05
Sterols
Cholesterol 4601.20 ± 9878.96 7633.19 ± 8383.76 NS
Desmosterol 167.78 ± 64.99 327.76 ± 127.00 NS
Lanosterol 76.86 ± 82.14 78.06 (1) NC
20a-hydroxycholesterol 59.65 ± 52.14 93.08 ± 24.37 NS
24S-hydroxycholesterol 53.36 ± 35.45 66.87 ± 30.67 NS
The number in the parentheses is the number of subject detected corresponding steroid.
aConcentrations are expressed as ng/g of creatinine (mean ± SD).
bNS, not significant.
cNC, not comparable.
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d., 0.33 μm film thickness; Agilent Technologies; Palo
Alto, CA). The GC oven temperature was initially set at
215°C, then ramped to 260°C at 1°C/min, and finally
increased to 320°C at 15°C/min and held for 1 min. The
carrier gas was helium at a column head pressure of
210.3 kPa (column flow: 1.0 mL/min at oven tempera-
ture of 215°C). For quantitative analysis, the characteris-
tic ions of each steroid were determined as their TMS
derivatives. Peak identifications were achieved by com-
paring the retention times and matching the height
ratios of the characteristic ions [17].
Statistical analysis
The levels of urinary steroids are reported as the mean
±S D .T h es i g n i f i c a n c eo ft h e s ev a r i a b l e so b t a i n e df r o m
the controls and PTC groups was examined using a Stu-
dent’s t-test. The variables in PTC were normalized to
the mean of the corresponding controls, and significance
of the normalized three groups was also evaluated by
one-way variance analysis (one-way ANOVA). A P-value
< 0.01 was considered significant. Partial least squares-
discrimination analysis (PLS-DA) with multivariate data
analysis software SIMCA-P (version 11.0, Umetrics Inc.,
Sweden) was used for clustering the study groups.
Multivariate data analysis
The processed data was stored in either Excel spread-
sheets or Comma Separated Values (CSV) formatted
files and then imported into SIMCA software. The urin-
ary steroid levels were classified by PLS-DA for pre- and
post-menopausal female and male PTC patients after
normalization. PLS-DA maximizes the covariance
between the predicting data set, which is X of the
numerical value of the targeted steroids, and Y of the
class assignment.
T h ef r a c t i o no ft h ev a r i a t i o ni nt h eYv a r i a b l e s
“explained” by the selected components (R
2Y), along
with the fraction of the variation of Y’s that can be “pre-
dicted” by a component according to cross validation
(Q
2Y) were calculated to plot and validate the model.
After calculating the components for the PLS-DA scat-
ter plot, the significant components were selected
according to the rule embedded in SIMCA-P software,
whereby Q
2 should be larger than zero for more than
100 observations and 0.05 for ≤ 100 observations. The
PLS-DA plots were then displayed as the superposition
of the highest two latent variables (t[1]/t[2] or p[1]/p[2]
as X-, Y- axes), such that most of the association with
dummy Y variables could be explained by the variations
in X. In addition, the high coefficient values of R
2Ya n d
Q
2Y revealed good discrimination. In this study, the
urinary steroids were scaled and centered prior to PLS-
DA. One point in the scatter plot represents the rates of
steroid secretion. The metabolic patterns can be inter-
preted using visual images or the R
2Y and Q
2Y values.
Results
Urinary levels of steroids in PTC patients
The urinary levels of 84 steroids in the pre- and post-
menopausal women and men with PTC, along with
their corresponding controls were profiled quantita-
tively. Tables 1, 2 and 3 list the concentrations in the
three PTC groups and their individual controls. In pre-
menopausal PTC women, all estrogens including estrone
(P < 0.008), 17b-estradiol (P < 0.008), 2-hydroxy-17b-
estradiol (P < 0.002), 4-hydroxy-17b-estradiol (P <
0.0003), 17-epiestriol (P < 0.003), 2-hydroxyestriol (P <
0.002) were increased, whereas 2-hydroxyestrone was
significantly decreased (P < 0.007). All androgens were
also up-regulated in the PTC patients including the
most active androgens, dihydrotestosterone (P <0 . 0 0 5 ) ,
androstenediol (P < 0.0002), and 16a-hydroxy DHEA (P
< 0.0002). Progestins tended to be higher in the PTC
patients, but the 5a-dihydroprogesterone levels were
slightly lower (P < 0.04). Both corticoids and sterols
were not significant (Table 1), whereas lanosterol was
detectable in only one patient.
In contrast, the levels of corticosterone (P <0 . 0 2 ) ,
dihydrodeoxycorticosterone (P < 0.02), tetrahydrocorti-
sol (P < 0.05) and tetrahydrocorticosterone (P <0 . 0 2 )
were slightly higher in the post-menopausal PTC
w o m e nt h a ni nt h ec o r r e s p o n d i n gc o n t r o l s( T a b l e2 ) .
Most estrogens could be up-regulated in the groups stu-
died but their urinary levels were undetectable in many
post-menopausal women in both the patient and control
groups. The levels of 5b-dihydrotestosterone were signif-
icantly higher in the patient group (P < 0.00003), but
this was not clinically meaningful. The other steroids,
progestins and sterols were not significant.
In PTC men, the 4-hydroxy-17b-estradiol (P <
0.00009), 2-methoxyestrone (P < 0.006) and 4-methox-
yestrone (P < 0.003) levels were significantly higher in
the patients, whereas 2-hydroxy-17b-estradiol levels
were lower (P < 0.00007; Table 3). In particular,
increased levels of 2-hydroxyestrone and decreased
levels of 2-hydroxy-17b-estradiol in the patients were
reversible with the results obtained from the PTC
women. Although the corticoids levels in the pre- and
post-menopausal women groups were not associated
with PTC, the levels of most corticoids were higher the
patients except for allodihydrocortisol (38.21 ± 28.01
ng/g creatinine for controls; 17.59 ± 8.64 for patients, P
< 0.005). Some active androgens including androstene-
dione (P < 0.002), androstenediol (P < 0.00005) and
16a-hydroxy-DHEA (P < 0.000005) in the patients were
associated with PTC. The levels of progestins and sterols
were not remarkable.
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Page 5 of 14Table 2 Concentrations of urinary steroids in post-menopausal PTC women and control
Steroids Concentration
a (mean ± SD) P-value
Controls
(n = 16)
PTC
(n = 19)
Controls : PTC
Androgens
Dihydrotestosterone 71.99 ± 45.10 91.87 ± 57.97 NS
b
Epidihydrotestosterone 38.16 ± 27.60 32.35 ± 58.50 NS
Dehydroepiandrosterone 165.46 ± 91.64 194.37 ± 109.70 NS
Testosterone 102.07 ± 64.62 196.74 ± 232.37 NS
Epitestosterone 92.02 ± 69.39 91.08 ± 60.77 NS
b
5a-androstan-3a,17b-diol 87.09 ± 64.60 112.99 ± 94.87 NS
5a-androstan-3b,17b-diol 4.26 (1) ND
c NC
d
5b-androstan-3a,17b-diol 99.98 ± 74.50 109.73 ± 90.40 NS
5b-androstan-3a,17a-diol 67.53 ± 62.11 61.33 ± 68.37 NS
5b-androstan-3b,17a-diol 14.33 ± 13.01 (2) 9.58 ± 7.20 (4) NC
5a-androstan-3b,17a-diol 22.27 ± 20.57 (2) 34.51 ± 28.74 (4) NC
5a-androstan-3a,17a-diol 43.24 ± 52.23 37.50 ± 24.00 NS
5b-androstan-3b,17b-diol ND 18.10 (1) NC
Androstenedione 110.21 ± 88.05 112.78 ± 59.83 NS
Androstenediol 54.27 ± 26.28 61.30 ± 13.63 NS
Androsterone 4464.11 ± 1786.06 14974.73 ± 17229.72 < 0.02
Etiocholanolone 4850.22 ± 2075.09 13920.59 ± 15821.56 < 0.03
11-keto-androsterone +
11-keto-etiocholanolone
580.33 ± 297.69 1727.55 ± 2045.94 < 0.03
11b-hydroxyandrosterone 4499.84 ± 2455.83 5488.85 ± 4203.96 NS
11b-hydroxyetiocholanolone 1462.44 ± 1071.41 2629.38 ± 2439.84 NS
5b-dihydrotestosterone 4.79 ± 1.61 21.03 ± 9.54 < 0.00003
16a-hydroxy-DHEA 228.48 ± 172.71 271.17 ± 127.46 NS
Epiandrosterone 60.19 ± 61.75 70.25 ± 35.51 NS
5a-Androstanedione 72.20 ± 83.17 (4) 60.13 ± 24.16 (13) NC
Estrogens
Estrone 163.00 ± 176.41 (6) 63.72 ± 47.10 (17) NC
17b-estradiol 14.24 ± 14.24 (4) 21.84 ± 19.84 (7) NC
Estriol 56.96 ± 65.77 (6) 60.11 ± 57.72 (17) NC
2-hydroxyestrone 306.99 ± 99.92 (5) 50.92 ± 30.20 (18) NC
2-hydroxy-17b-estradiol 131.39 ± 166.91 (6) 168.07 ± 372.40 (17) NC
4-hydroxyestrone 76.21 ± 15.24 (4) 42.27 ± 49.44 (15) NC
4-hydroxy-17b-estradiol 33.90 ± 13.10 (4) 44.94 ± 23.08 (16) NC
2-methoxyestrone 69.67 ± 77.40 (6) 101.47 ± 68.85 (7) NC
2-methoxy-17b-estradiol 24.53 ± 11.18 (3) 60.09 ± 29.12 (7) NC
4-methoxyestrone 32.32 (1) 85.60 ± 41.64 (15) NC
4-methoxy-17b-estradiol 66.69 ± 75.09 (4) 55.39 ± 11.16 (4) NC
17-epiestriol 254.59 (1) 94.42 ± 44.07 (8) NC
16-epiestriol 74.15 ± 85.83 (6) 119.59 ± 63.08 (6) NC
17a-estradiol ND ND NC
2-hydroxyestriol ND 90.89 ± 102.52 (5) NC
16-keto-17b-estradiol +
16a-hydroxyestrone
28.01 ± 33.72 (6) 46.10 ± 24.21 (18) NC
Corticoids
Cortisol 235.02 ± 205.57 561.28 ± 345.19 NS
Allodihydrocortisol 71.42 ± 64.96 61.67 ± 84.03 NS
Corticosterone 20.74 ± 5.63 100.83 ± 85.62 < 0.02
Allodihydrocorticosterone 53.16 ± 46.48 66.19 ± 38.41 NS
Dihydrodeoxycorticosterone 20.41 ± 15.52 162.62 ± 155.03 < 0.02
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Page 6 of 14In all cases, androgens were up-regulated in the
patient groups compared to the control groups. Among
the urinary androgens studied, five androgens (andros-
terone, etiocholanolone, 11-keto-androsterone, 11-keto-
etiocholanolone and 5b-DHT), which are abundant ster-
oids in humans, were significantly higher in all patient
g r o u p s( T a b l e s1 ,2 ,a n d3 ) .A c t i v ea n d r o g e n si n c l u d i n g
androstenedione, androstenediol and 16a-hydroxy
DHEA were significantly higher in the pre-menopausal
women and men with PTC, but not in the post-meno-
pausal PTC women. Estrogens were also up-regulated in
all patients compared to the controls. In particular, the
2-hydroxyestrone level was lower in the pre-menopausal
PTC women (P < 0.007) but higher in the PTC men (P
< 0.02). In contrast, 2-hydroxy-17b-estradiol was higher
in the pre-menopausal PTC women (P < 0.002), whereas
Table 2 Concentrations of urinary steroids in post-menopausal PTC women and control (Continued)
11-deoxycorticosterone 101.66 ± 97.56 61.76 ± 29.06 NS
11-deoxycortisol 101.54 ± 102.04 45.92 ± 22.60 NS
Cortisone 980.80 ± 750.48 2205.39 ± 2667.76 NS
Allotetrahydrocortisol 9613.87 ± 6293.12 17105.92 ± 16369.40 NS
21-deoxycortisol 86.96 ± 32.86 97.31 ± 54.06 NS
11-dehydrocorticosterone 124.14 ± 75.34 194.61 ± 298.04 NS
Tetrahydrodeoxycortisol 794.79 ± 305.00 818.38 ± 581.02 NS
Tetrahydrocortisone 17811.52 ± 12271.25 16114.72 ± 12222.84 NS
Tetrahydrocortisol 8640.16 ± 4558.83 16040.33 ± 12750.63 < 0.05
Tetrahydrodeoxycorticosterone 56.16 ± 73.09 43.58 ± 61.64 NS
Tetrahydrocorticosterone 389.66 ± 207.67 780.31 ± 575.27 < 0.02
11-dehydrotetrahydrocorticosterone 877.74 ± 538.13 1445.62 ± 1602.49 NS
a-cortolone 4888.98 ± 2535.86 29149.71 ± 97516.67 NS
b-cortolone 2589.95 ± 927.40 5524.05 ± 11016.02 NS
20a-dihydrocortisone 375.30 ± 192.08 1766.88 ± 5192.38 NS
a-cortol 944.46 ± 362.03 5294.32 ± 17534.68 NS
b-cortol 2299.34 ± 908.51 8550.42 ± 23540.39 NS
20a-dihydrocortisol 172.51 ± 127.47 786.04 ± 2141.06 NS
Progestins
Pregnenolone 66.45 ± 68.65 108.91 ± 65.30 NS
Progesterone ND 47.86 (1) NC
5b-dihydroprogesterone 13.35 ± 9.78 ND NC
5a-dihydroprogesterone 38.87 ± 28.09 (2) 24.96 ± 37.35 NC
20a-hydroprogesterone 121.40 ± 105.37 (3) 276.33 ± 450.77 NC
Epipregnanolone 63.07 ± 63.10 37.64 ± 22.54 NS
Pregnanolone 652.71 ± 1018.03 489.54 ± 1157.06 NS
Allopregnanolone 147.26 ± 129.01 109.29 ± 187.61 NS
Isopregnanolone 60.44 ± 5.17 (3) 73.12 ± 43.22 NC
Pregnanediol 6959.54 ± 12541.46 3635.06 ± 9400.59 NS
Pregnanetriol 1559.68 ± 1314.30 2612.22 ± 3133.33 NS
17a-hydroxypregnenolone 85.37 ± 85.75 106.24 ± 57.67 NS
17a-hydroxyprogesterone ND 133.63 ± 84.38 NC
11b-hydroxyprogesterone 1204.77 ± 516.99 6580.30 ± 17763.59 NS
Sterols
Cholesterol 5103.58 ± 3075.92 (6) 5002.90 ± 3033.29 NC
Desmosterol 197.65 ± 67.86 (2) ND NC
Lanosterol 102.03 ± 125.18 (4) 32.83 ± 20.51 (3) NC
20a-hydroxycholesterol ND 86.56 ± 4.77 (2) NC
24S-hydroxycholesterol 116.58 ± 101.37 (4) 54.63 ± 26.17 (7) NC
The number in the parentheses is the number of subject detected corresponding steroid.
aConcentrations are expressed as ng/g of creatinine (mean ± SD).
bNS, not significant.
cND, not detected.
dNC, not comparable.
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Page 7 of 14Table 3 Concentrations of urinary steroids in the PTC men and control
Steroids Concentration
a (mean ± SD) P-value
Controls
(n = 20)
PTC
(n = 16)
Controls : PTC
Androgens
Dihydrotestosterone 91.39 ± 62.43 132.14 ± 92.41 NS
b
Epidihydrotestosterone 20.74 ± 16.54 28.45 ± 14.21 NS
Dehydroepiandrosterone 144.93 ± 58.60 180.74 ± 85.79 NS
Testosterone 101.16 ± 89.00 271.30 ± 270.50 NS
Epitestosterone 181.57 ± 93.89 177.67 ± 111.44 NS
5a-androstan-3a,17b-diol 381.95 ± 183.28 320.57 ± 198.42 NS
5a-androstan-3b,17b-diol 3.70 ± 3.66 83.37 ± 99.92 NS
5b-androstan-3a,17b-diol 432.61 ± 362.77 607.93 ± 1056.85 NS
5b-androstan-3a,17a-diol 55.09 ± 46.59 109.91 ± 153.06 NS
5b-androstan-3b,17a-diol ND
c 4.92 (1) NC
d
5a-androstan-3b,17a-diol 31.72 ± 39.33 54.92 ± 80.93 NS
5a-androstan-3a,17a-diol 31.13 ± 28.59 40.00 ± 63.40 NS
5b-androstan-3b,17b-diol 2.51 (1) ND NC
Androstenedione 40.66 ± 21.23 92.10 ± 51.74 < 0.002
Androstenediol 28.68 ± 12.20 82.31 ± 38.09 < 0.00005
Androsterone 10087.69 ± 4603.39 26110.67 ± 11663.35 < 0.00006
Etiocholanolone 8256.47 ± 3997.97 24745.49 ± 16868.98 < 0.002
11-keto-androsterone +
11-keto-etiocholanolone
531.90 ± 598.85 1660.94 ± 1191.92 < 0.003
11b-hydroxyandrosterone 4009.02 ± 2754.69 7037.26 ± 4372.55 < 0.02
11b-hydroxyetiocholanolone 1295.60 ± 1325.27 2087.71 ± 1610.32 NS
5b-dihydrotestosterone 3.01 ± 1.85 17.67 ± 20.67 < 0.02
16a-hydroxy-DHEA 79.37 ± 43.01 186.33 ± 63.29 < 0.000005
Epiandrosterone 24.21 ± 10.91 46.90 ± 33.66 < 0.02
5a-Androstanedione 11.29 (1) 24.39 (1) NC
Estrogens
Estrone 39.69 ± 12.89 60.18 ± 29.20 < 0.02
17b-estradiol 12.91 ± 12.56 15.05 ± 10.68 NS
Estriol 24.62 ± 11.84 44.79 ± 31.46 < 0.03
2-hydroxyestrone 50.27 ± 25.50 91.83 ± 55.12 < 0.02
2-hydroxy-17b-estradiol 195.56 ± 113.59 64.98 ± 38.05 < 0.00007
4-hydroxyestrone 51.38 ± 26.59 59.70 ± 24.78 NS
4-hydroxy-17b-estradiol 18.29 ± 7.63 42.05 ± 13.14 < 0.00009
2-methoxyestrone 22.78 ± 13.07 42.46 ± 20.94 < 0.006
2-methoxy-17b-estradiol 19.41 ± 9.13 27.37 ± 14.25 NS
4-methoxyestrone 17.78 ± 7.24 34.29 ± 16.50 < 0.003
4-methoxy-17b-estradiol 19.00 ± 9.90 28.78 ± 11.78 < 0.03
17-epiestriol 42.81 (1) 49.14 ± 5.76 (2) NC
16-epiestriol 28.28 ± 19.49 34.70 ± 16.18 NS
17a-estradiol 0.92 (1) ND NC
2-hydroxyestriol 0.57 ± 0.77 40.82 ± 69.05 NS
16-keto-17b-estradiol +
16a-hydroxyestrone
9.99 ± 4.63 22.93 ± 10.98 < 0.0003
Corticoids
Cortisol 183.91 ± 160.81 487.21 ± 482.28 < 0.03
Allodihydrocortisol 38.21 ± 28.01 17.59 ± 8.64 < 0.005
Corticosterone 33.47 ± 32.89 56.57 ± 91.42 NS
Allodihydrocorticosterone 22.53 ± 10.10 29.87 ± 13.54 NS
Dihydrodeoxycorticosterone 32.30 ± 37.87 134.38 ± 105.38 < 0.02
Choi et al. BMC Cancer 2011, 11:342
http://www.biomedcentral.com/1471-2407/11/342
Page 8 of 14its level was lower in PTC men (P < 0.00007). Two
hydroxylated estrogens at C-2 showed different biologi-
cal actions between genders. Corticoids were slightly
higher in the PTC men and post-menopausal PTC
women but not in pre-menopausal PTC women. Proges-
tins were also higher in the patients except for post-
menopausal PTC women. In this study, no sterols were
shown to be significant in the PTC groups.
Group differences in the steroid metabolism
To exclude the nature of menopause and gender differ-
ences between the patient groups studied, all steroid
levels in the PTC groups were normalized to the mean
values of the corresponding controls, and the different
pathogenesis of PTC was then compared according to
the menopausal and gender conditions. Statistical analy-
sis was performed using PLS-DA with normalized levels
Table 3 Concentrations of urinary steroids in the PTC men and control (Continued)
11-deoxycorticosterone 28.74 ± 15.27 28.78 ± 13.55 NS
11-deoxycortisol 37.14 ± 16.35 32.66 ± 15.58 NS
Cortisone 511.43 ± 377.83 1580.13 ± 1320.58 < 0.006
Allotetrahydrocortisol 9510.49 ± 4735.51 20666.67 ± 12334.24 < 0.003
21-deoxycortisol 63.27 ± 29.68 88.63 ± 45.03 NS
11-dehydrocorticosterone 110.59 ± 105.33 148.87 ± 147.64 NS
Tetrahydrodeoxycortisol 405.48 ± 214.37 756.82 ± 539.85 < 0.03
Tetrahydrocortisone 11055.45 ± 5289.49 18809.78 ± 11894.93 < 0.03
Tetrahydrocortisol 6091.23 ± 2812.78 16371.31 ± 10629.87 < 0.002
Tetrahydrodeoxycorticosterone 24.76 ± 15.31 37.50 ± 24.52 NS
Tetrahydrocorticosterone 433.03 ± 604.84 659.73 ± 380.95 NS
11-dehydrotetrahydrocorticosterone 993.99 ± 1013.47 1127.02 ± 618.49 NS
a-cortolone 4030.85 ± 1778.81 6992.04 ± 3748.34 < 0.009
b-cortolone 2284.12 ± 1041.75 3306.24 ± 1662.55 < 0.05
20a-dihydrocortisone 252.58 ± 107.63 431.88 ± 202.66 < 0.005
a-cortol 838.32 ± 319.86 1180.62 ± 550.93 < 0.04
b-cortol 2181.33 ± 886.33 3316.76 ± 1830.36 < 0.04
20a-dihydrocortisol 87.90 ± 57.63 188.16 ± 129.88 < 0.01
Progestins
Pregnenolone 27.08 ± 13.26 41.82 ± 15.30 < 0.02
Progesterone 22.47 ± 11.45 (2) 47.85 ± 10.86 (3) NC
5b-dihydroprogesterone 7.90 ± 7.77 11.18 NS
5a-dihydroprogesterone 24.37 ± 11.29 28.45 ± 35.05 NS
20a-hydroprogesterone 35.96 ± 24.53 76.35 ± 54.00 < 0.01
Epipregnanolone 13.87 ± 8.23 16.85 ± 6.83 NS
Pregnanolone 251.57 ± 121.38 559.35 ± 835.31 NS
Allopregnanolone 55.53 ± 25.97 92.13 ± 129.62 NS
Isopregnanolone 32.57 ± 11.39 47.07 ± 24.81 NS
Pregnanediol 1896.17 ± 1077.27 5669.51 ± 10408.32 NS
Pregnanetriol 2704.00 ± 1146.97 3975.05 ± 1957.07 < 0.04
17a-hydroxypregnenolone 39.84 ± 22.13 58.70 ± 38.95 NS
17a-hydroxyprogesterone 15.19 (1) 39.82 ± 19.99 NC
11b-hydroxyprogesterone 818.94 ± 373.38 2518.86 ± 1739.51 < 0.002
Sterols
Cholesterol 2028.74 ± 1781.46 3851.26 ± 2743.30 < 0.04
Desmosterol 216.36 ± 88.55 421.52 ± 622.80 NS
Lanosterol 58.32 ± 73.89 43.89 ± 30.30 NS
20a-hydroxycholesterol 49.98 (1) 85.15 (1) NC
24S-hydroxycholesterol 111.65 ± 207.00 27.96 ± 15.91 NS
The number in the parentheses is the number of subject detected corresponding steroid.
aConcentrations are expressed as ng/g of creatinine (mean ± SD).
bNS, not significant.
cND, not detected.
dNC, not comparable.
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Page 9 of 14of steroids in the three groups (Additional file. 1). Using
the visual inspecting metabolic patterns of steroids and
the coincidences between R
2Ya n dQ
2Y, the pre- and
post-menopausal women, and male groups with PTC
were clustered individually (Additional file 1A). Their
metabolic patterns were discriminated clearly (R
2Y=
0.727, Q
2Y = 0.558). The loading plot of PLS-DA, which
is complement to the score plot due to the transposed
matrix calculation, was also performed to identify the
possible urinary biomarkers. Each data point represents
one particular steroid with the relationship between the
different PTC patients (Additional file 1B). The meta-
bolic differentiation between the groups complemented
the results listed in Additional file 2.
Several possible biomarkers for individual PTC groups
were selected (Additional file 2). The levels of androste-
nediol (P < 0.005) was significantly higher in the PTC
m e nt h a ni nb o t hP T Cw o m e ng r o u p s ,w h e r e a s1 6 a-
hydroxy DHEA was higher in both pre-menopausal and
men with PTC (P < 0.002). The normalized androgens
levels in PTC men were significantly higher than nor-
malized pre- or post-menopausal PTC women (andros-
tenediol, P < 0.005; 16a-hydroxy-DHEA, P <0 . 0 0 2 )
(Additional file 2). In both PTC women groups, corti-
costerone (P < 0.005) and dihydrodeoxycorticosterone
(P < 0.009) were higher in the post-menopausal PTC
women group than in the pre-menopausal PTC women
and PTC men, whereas the post-menopausal PTC
women showed lower levels of 11-deoxycorticosterone
(P < 0.003). The normalized corticoids levels (corticos-
terone, P < 0.005; dihydrodeoxycorticosterone, P <
0.009; 11-deoxycorticosterone, P < 0.003) of post-meno-
pausal PTC women were significantly higher than in the
other groups (Additional file 2). In progestins, only epi-
pregnanolone showed a significance in post-menopausal
PTC women compared to both pre-menopausal and
men with PTC (P < 0.0004). In the case of 24S-hydroxy-
cholesterol, its urinary concentrations were not remark-
able in any of the groups compared, but the normalized
values were significantly higher in the pre-menopausal
PTC women (P < 0.000002). Estrogens (estrone, P <
0.0001, 2-hydroxy-17b-estradiol, P < 0.002; 4-hydroxyes-
trone, P < 0.001; 4-hydroxy-17b-estradiol, P < 0.006; 17-
epiestriol, P < 0.0008) in the pre-menopausal PTC
women were significantly higher than those of post-
menopausal women and men with PTC, whereas 2-
hydroxyestrone was significantly higher in PTC men (P
< 0.0000001).
To demonstrate the enzyme activities in the steroid
metabolism, the ratio of the steroid metabolite to pre-
cursor was examined. Box plots of the altered steroids
normalized in all PTC patients showed differences in
these ratios (Figure 1). The 16a-hydroxylation of DHEA
was differentiated between pre-menopausal women and
men with PTC (Figure 1A). In the case of 2-hydroxyla-
tion, all PTC groups were significantly discriminated
with the 2-hydroxyestrone to estrone ratio (Figure 1B),
whereas the 2-hydroxy-17b-estradiol to 17b-estradiol
ratio could differentiate the pre-menopausal PTC
women with post-menopausal PTC women and PTC
men (Figure 1C). For 2-methoxylation, all groups were
differentiated with the ratio of 2-methoxyestrone to 2-
hydroxyestrone (Figure 1D), whereas 17b-estradiol
represented the pre-menopausal women and men with
PTC groups (Figure 1E). 4-methoxylation with the 4-
methoxyestrone to 4-hydroxyestrone ratio showed dif-
ferences between post-menopausal PTC women and the
other two PTC groups (Figure 1F), whereas 4-hydroxy-
17b-estradiol differentiated between pre-menopausal
women and men with PTC (Figure 1G). There were sta-
tistically significant differences found in the estrogen
metabolites ratio of 2-hydroxyestrone to 2-hydroxy-17b-
estradiol, which could indicate 17b-hydroxysteroid dehy-
drogenase (17b-HSD) between women and men with
PTC (< 4 × 10
-7; Figure 2).
Discussion
Although an understanding of the pathogenesis and
development in PTC has been investigated, there is no
data available on the metabolic alteration of steroids
according to gender and menopausal condition. The
metabolic profiling of urinary steroids in pre- and post-
menopausal women, and men with PTC were achieved.
Due to gender and menopausal variations in steroid bio-
synthesis, each patient group was normalized to the cor-
responding control group before comparing the patient
groups.
ERa causes cell proliferation and progress in PTC
[7,12,19]. The level of ERa is higher in PTC cells than
normal cells, and is higher in pre-menopausal women
than in both post-menopausal women and men with
PTC [7]. The urinary levels of estrogens in pre-meno-
pausal women were investigated first. The concentra-
tions of all estrogens in the pre-menopausal PTC
women were higher than the controls, except for 2-
hydroxyestrone, which was significantly lower (Table 1).
T h ee x t e n tt ow h i c ht h e2 - h y d roxyestrogens are active
or can form active or genotoxic metabolites is contro-
versial [20,21]. 2-hydroxyestrone has been characterized
as the “good estrogen” [22]. In addition, the normalized
levels of estrone, 2-hydroxy-17b-estradiol, 4-hydroxyes-
trone, and 4-hydroxy-17b-estradiol were also signifi-
cantly higher in pre-menopausal PTC women than
normalized post-menopausal women and men with
PTC, whereas the level of 2-hydroxyestrone was signifi-
cantly up-regulated in PTC men (Additional file 2). In
addition, the estrogen metabolism has been shown to
potentiate the growth of hormone related cancers, such
Choi et al. BMC Cancer 2011, 11:342
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Figure 1 Enzyme activities based on the normalized levels of urinary steroids from pre- and post-menopausal women and men with
PTC. The level differences significant at the P < 0.01 were selected. Line within the box represents the median, lower boundary of the box
indicates 25%, and the upper boundary of the box indicates 75%. Whiskers above and below indicate the maximum and minimum steroid levels.
Dots above and below indicate the plot outliers with the 10
th and 90
th percentiles.
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Page 11 of 14as breast and cervical cancer [23,24]. 2-Hydroxyestrone
and 16a-hydroxyestrone as the oxidative metabolites of
estrone have different biological actions with anti-prolif-
eration and proliferative effects, respectively, in hormone
related cancers [24,25].
In this study, 16a-hydroxyestrone was not exactly
quantified because of its co-elution with 16-keto-17b-
estradiol during chromatographic separation. In addi-
tion, 4-hydroxyestrone generates reactive oxygen species
(ROS) as a source of oxidative stress through estrogen
metabolic redox cycling [26] and increases the formation
of endogenous carcinogens [24]. Here, 4-hydroxyestro-
gens was increased significantly, whereas 2-hydroxyes-
trone was decreased in both PTC women groups
(Tables 1, 2 and 3). In general, 2-hydroxyestrone does
n o th a v ee s t r o g e n i ca c t i v i t yp e r i p h e r a l l ya n dm a yb e
anti-estrogenic, leading to an anti-proliferative effect on
estrogen-sensitive cells as the good estrogen [27].
AR causes cell proliferation in PTC [15] and its activity
is higher in men than women, and is more active in PTC
cells than normal cells [14-16]. Nevertheless, the concen-
trations of most estrogens, except for 2-hydroxy-17b-
estradiol, and androgens (androstenedione, androstene-
diol, androsterone, etiocholanolone, and 16a-hydroxy-
D H E A )i nP T Cm e nw e r eh i g h e rt h a nt h ec o n t r o l s
(Table 3). The normalized levels of androstenediol and
16a-hydroxy-DHEA in PTC men were significantly
higher than normalized pre- or post-menopausal PTC
w o m e nt h r o u g ht h eh i g h e ra n d r o g e nl e v e l si nm e n
(Additional file 2). In addition, the levels of AR were
increased by a testosterone treatment in PTC [28]. In this
study, the normalized levels of testosterone in PTC men
were more significant than pre- or post-menopausal PTC
women through AR activation, and the normalized levels
of androstenedione and androstenediol as a precursor of
testosterone in PTC males were more significant than in
the other PTC groups (Additional file 2).
Based on their metabolic actions, corticoids are
divided by glucocorticoids and mineralocorticoids, [29]
and they are generally considered to simulate lipogen-
esis, and accelerate fatty acid synthesis [30,31]. There-
fore, the concentrations of both corticoids series, such
as corticosterone, dihydrodeoxycorticosterone, tetrahy-
drocortisol, and tetrahydrocorticosterone in post-meno-
pausal PTC women are higher than its controls (Table
2). However, the normalized levels of mineralocorticoids
including corticosterone, dihydrodeoxycorticosterone,
and 11-deoxycorticosterone in post-menopausal PTC
women were significantly higher than in the other
groups (Additional file 2).
Many steroids and metabolic ratios indicate both
menopausal and gender differences in PTC progression
(Figure 1) but their levels are discriminated by the
degree of up-regulation in PTC patients. In particular,
2-hydroxyestrone and 2-hydroxy-17b-estradiol show
reversible actions between pre-menopausal women and
men with PTC (Tables 1 and 3). 2-hydroxyestrone sti-
mulates the anti-proliferation of cancer cells directly,
whereas the effect of 2-hydroxy-17b-estradiol on carci-
nomas is more complex. In addition, 2-hydroxy-17b-
estradiol was up-regulated in the pre-menopausal PTC
women and its production may result in oxidative DNA
damage and apoptosis in human mammalian cells [32].
Inter-conversion between 2-hydroxyestrone and 2-
hydroxy-17b-estradiol catalyzed by 17b -HSD was signif-
icantly altered in PTC men against both pre- and post-
menopausal women with PTC (Figure 2). The expres-
sion of 17b-HSD is not only specific in thyroid disorders
[7], but may indicate the gender differences. However,
its reversible actions in men have not been investigated.
Conclusions
Although both most androgens and estrogens were
increased in the pre-menopausal women with PTC in
this study, hydroxylation and methoxylation with estro-
gens explained more the metabolic changes between all
groups studied. In this cross-sectional study, the thyroid
cancer risk might be associated with lower 2-hydroxya-
tion activities of either estrone or 17b-estradiol in
women and men. Overall, the 2-hydroxyestrone to 2-
hydroxy-17b-estradiol metabolic ratio, which indicates
the activity of 17b-HSD, may in fact be gender differ-
ences in the thyroid cancer progression. These results
may help better understand the pathogenesis of PTC
according to gender and menopausal conditions.
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Page 12 of 14Additional material
Additional file 1: PLS-DA score (A) and loading (B) plots from a
profiling of 84 urinary steroids. The steroid profiling of pre- and post-
menopausal female, and male patients with papillary thyroid carcinoma
(PTC) was conducted. The levels of urinary steroids were normalized to
the mean values of individual control groups and then differentiated by
one-way ANOVA. The abbreviation of the steroids in the loading plot
was obtained from reference 20.
Additional file 2: Levels of normalized urinary steroids in the pre-
and post-menopausal women and men with PTC. To exclude the
nature of menopause and gender differences between the patient
groups studied, all steroid levels in the PTC groups were normalized to
the mean values of the corresponding controls, and the normalized
differentiation proposed several possible biomarkers.
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